ARTICLE | Clinical News
Episalvan: Ph III EASE start
March 9, 2017 1:15 PM UTC
This month, Amryt will begin the double-blind, placebo-controlled, international Phase III EASE trial to evaluate topical Episalvan for 90 days in about 164 patients. Episalvan is approved in the EU t...
BCIQ Company Profiles